NVRO continues to gain due to its business expansion into the SI joint fusion market and optimistic 2024 results amid a weak SCS market.

Nevro Corp. (NYSE:NVRO – Get Free Report) has earned a consensus rating of “Reduce” from the thirteen research firms that are ...

Analysts at StockNews.com initiated coverage on shares of Nevro (NYSE:NVRO – Get Free Report) in a research note issued on ...

Nevro (NVRO) came out with a quarterly loss of $0.64 per share versus the Zacks Consensus Estimate of a loss of $0.79. This compares to loss of $0.15 per share a year ago. These figures are ...

NEVRO ($NVRO) is expected to release its quarterly earnings data on Tuesday, March 4th after market close, per Finnhub. Analysts are expecting revenue of $104,594,880 ...

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Alpha Teknova (TKNO – Research Report), Wave Life Sciences ...

The Redwood City, California-based company said it had a loss of $1.41 per share. Losses, adjusted for one-time gains and costs, came to 64 cents per share. The results surpassed Wall Street ...

Op dinsdag handhaafden analisten van Stifel hun koopadvies en koersdoel van $ 94,00 voor aandelen van Globus Medical (NYSE:GMED), met focus op de fusierichtlijnen en potentiële winst per aandeel (EPS) ...

TORONTO, March 03, 2025 (GLOBE NEWSWIRE) -- EnviroGold Global Limited (CSE: NVRO | OTCQB: ESGLF | FSE: YGK) (“EnviroGold,” or the “Company”), a clean technology company that monetises mine waste and ...

NVRO)’s sale to Globus Medical for $5.85 per share. If you are a Nevro shareholder, click here to learn more about your rights and options. Triumph Group, Inc. (NYSE: TGI)’s sale to affiliates ...